Dasanat contains dasatinib, a potent oral medication used in the treatment of certain blood cancers. It is most commonly prescribed for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL). Dasatinib belongs to a class of targeted therapies known as tyrosine kinase inhibitors, which help stop the growth and multiplication of cancer cells.

Approved for use in both adults and children, dasatinib offers a critical option when other treatments are not effective or when resistance develops.

Dasatinib works by inhibiting BCR-ABL tyrosine kinase, an abnormal enzyme produced by cancer cells in certain types of leukemia. This enzyme is the result of a genetic mutation called the Philadelphia chromosome, which drives uncontrolled cell growth in leukemia.

In addition to BCR-ABL, dasatinib also inhibits other kinases such as:

• SRC-family kinases

• c-KIT

• PDGFR

  Uses

  Dasanat (dasatinib) is used to treat the following conditions:

  • Chronic Myeloid Leukemia (CML)
    For adults and children with newly diagnosed CML or those who are resistant or intolerant to prior therapy.

  • Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-positive ALL)
    Used in patients with resistance or intolerance to previous treatments.

    Adverse Effects

    While dasatinib is generally well-tolerated, like all cancer therapies, it can cause side effects. These should be monitored and managed by the healthcare team.

    Common Side Effects

    • Fluid retention including swelling around the eyes or in the lower legs

    • Fatigue and weakness

    • Headache

    • Nausea or vomiting

    • Diarrhea

    • Skin rash

    • Low blood counts including white cells, red cells, or platelets